SharpyWegovy Sales 2026: What Novo's Q3 Numbers Mean for You
Wegovy sales in 2026 are shifting from the pen to the pill. In its third-quarter report on November 4, 2026, Novo Nordisk said the Wegovy pill made DKK 5.4 billion in the quarter, had about 3.6 million US prescriptions and an estimated 80% share of new-to-brand US prescriptions, while US sales of the Wegovy pen fell 13%. For patients, that means steady supply, self-pay pill prices of $149 to $299 a month, and a $675 list price from January 1, 2027. Whichever form you use, Sharpy helps you protect muscle with one protein target, one 20-minute workout and one Shape Score a day.
How are Wegovy sales doing in 2026, and does it matter to you as a patient? The short answer: Wegovy is growing again, and the pill is why. In its third-quarter report on November 4, 2026, Novo Nordisk estimated the Wegovy pill's share of new-to-brand US prescriptions at about 80%. Sales of the Wegovy pen fell 13% in the US. Novo also raised its 2026 outlook for the third time this year.
For patients, the numbers point to three things: supply is steady, prices keep falling, and more people are starting on a daily pill instead of a weekly shot. Here is what the report says, in plain English.
Wegovy sales 2026: the Q3 numbers at a glance
Novo reports in Danish kroner (DKK). All growth figures below are at constant exchange rates (CER), which strips out currency swings.
| Product (Q3 2026) | Sales | Change vs Q3 2025 |
|---|---|---|
| Wegovy pen, worldwide | DKK 20,407 million | Down 2% |
| Wegovy pen, US only | Not given in DKK | Down 13% |
| Wegovy pen, outside US | Not given in DKK | Up 16% |
| Wegovy pill, worldwide | DKK 5,394 million | New (launched Jan 2026) |
| Wegovy pill, US only | DKK 4,178 million | New |
| Wegovy pen plus pill, US | Up 21% | |
| Wegovy pen plus pill, outside US | Up 31% | |
| Ozempic pen, worldwide | DKK 29,706 million | Down 5% |
The Wegovy pill's DKK 5.4 billion is roughly US$800 million, based on the conversion reported by Analytics Insight. Over the first nine months of 2026, the pill made DKK 10.9 billion.
Wegovy pill sales 2026: how fast is it growing?
Fast. Novo shared these numbers in the report:
- About 3.6 million Wegovy pill prescriptions were filled in the US in the third quarter.
- More than 8 million have been filled since the US launch on January 5, 2026.
- About 80% is Novo's estimate of the pill's US new-to-brand prescription share.
- About 55,000 people had an active Wegovy subscription (3, 6 or 12 months) at the end of September.
The pill is now sold in eight countries, including the US, the UK, Germany, France, Spain, Poland, Mexico and the UAE. Novo plans more than 20 markets in 2027. Outside the report, Brazil's drug agency Anvisa approved the Wegovy pill on November 4, 2026, and Australia approved it earlier this week, as we covered in Wegovy pill Australia. Prices and launch dates in Brazil are not set yet.
Why are people choosing the pill? It is one 25 mg tablet a day once you reach the full dose, with no needles, and it costs less when paying cash. It does have strict rules: take it on an empty stomach with a small sip of water, then wait 30 minutes before eating. Our Wegovy pill dosage chart explains the label steps. If you are deciding between pills, see Wegovy pill vs Foundayo.
Why are Wegovy pen sales down in the US?
Three reasons show up in the report:
- People moved to the pill. Many new patients start on tablets instead of the pen.
- Lower prices. Novo cites "lower realised prices" in the US. More people now pay cash at discounted prices; about 35% of the 4.1 million US Wegovy pen prescriptions in the quarter went through the self-pay channel.
- Less Medicaid coverage. Novo lists reduced obesity drug coverage in Medicaid as a drag on US sales.
The high-dose pen, Wegovy HD (7.2 mg), made up about 5% of Wegovy pen prescriptions. For how it stacks up, read Wegovy HD vs Zepbound.
How much will Wegovy cost in 2026 and 2027?
Lower sales per pen do not mean higher prices for you. The trend runs the other way.
| How you pay | Price | Notes |
|---|---|---|
| Wegovy pill, self-pay | $149 to $299 a month | Depends on dose (Novo Q3 report) |
| Wegovy pen, self-pay (NovoCare, TrumpRx) | $349 a month | $399 at 7.2 mg, as of our Oct 2026 check |
| Wegovy list price, from Jan 1, 2027 | $675 a month | Down about 50%; helps coinsurance and high-deductible plans |
| Medicare GLP-1 Bridge | $50 a month copay | Coverage started July 1, 2026 |
For the details, see our guides to the Wegovy pill cost, the 2027 price cut and the Medicare GLP-1 Bridge.
Cheaper access means more people losing weight quickly, and fast weight loss can take muscle with it. That is where Sharpy fits in. It gives you one daily protein target, one 20-minute strength workout and a Shape Score, so you can see that you are losing fat, not muscle. Not sure how much protein you need? Start with our protein target guide.
What is Novo Nordisk's 2026 outlook?
Novo now expects 2026 adjusted sales and adjusted operating profit to land between -2% and +2% at constant exchange rates. In August it expected -6% to 0%. The company said the raise was "mainly driven by increased expectations for GLP-1 product sales."
Other news from the report that may matter to patients:
- CagriSema, Novo's next weight-loss shot, is being prepared for a US launch in early 2027, if the FDA approves it. See our CagriSema guide.
- Ozempic 25 mg pill: an FDA decision is expected in the fourth quarter of 2026. Read about the current Ozempic pill.
- Wegovy pill for MASH, a fatty liver disease, has been submitted to the FDA. The shot is already approved for it, as our Wegovy MASH guide explains.
What the Wegovy earnings report means for you
- Supply looks steady. Semaglutide has been off the FDA shortage list since February 2025, and Novo is adding countries, not rationing.
- Ask about the pill if needles are a barrier. Switching forms is a prescriber decision. Do not change or stop your medicine on your own.
- Check your 2027 plan. Open enrollment is a good time to compare what you will pay under the new list price.
- Protect your muscle. Whatever form you take, eat protein at every meal and lift something two or three times a week. Sharpy keeps it simple: one target, one workout, one score a day.
Sources
- Novo Nordisk company announcement No 65/2026, third quarter 2026 (SEC Form 6-K, Nov 4, 2026)
- Analytics Insight: Novo Nordisk raises 2026 outlook, Wegovy pill sales (Nov 2026)
- Metrópoles: Anvisa approves first pill version of Wegovy (Nov 4, 2026, in Portuguese)
- Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (Feb 24, 2026)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (shortage status)
Questions people ask
How are Wegovy sales doing in 2026?
Combined Wegovy sales (pen plus pill) grew 21% in the US and 31% outside the US in the third quarter of 2026, at constant exchange rates, according to Novo Nordisk. The growth came from the pill. US sales of the Wegovy pen fell 13% in the quarter, as many people moved to the pill or paid lower prices.
How much did the Wegovy pill sell in 2026?
The Wegovy pill made DKK 5,394 million in the third quarter of 2026 (roughly US$800 million) and DKK 10,868 million in the first nine months. About DKK 4.2 billion of the third-quarter sales came from the US.
How many people take the Wegovy pill?
Novo did not give a patient count. It said about 3.6 million Wegovy pill prescriptions were filled in the third quarter and more than 8 million since the US launch on January 5, 2026. One person can fill many prescriptions in a quarter, so prescriptions are not the same as patients.
Did Novo Nordisk raise its 2026 outlook?
Yes. On November 4, 2026, Novo raised its 2026 outlook for adjusted sales and adjusted operating profit to between -2% and +2% at constant exchange rates, up from -6% to 0% in August. It said the raise came mainly from higher expected GLP-1 sales.
Is Wegovy getting cheaper in 2027?
The list price is. Novo Nordisk is lowering the US list price of Wegovy, Ozempic and Rybelsus to $675 a month on January 1, 2027, about 50% off Wegovy. Self-pay prices are separate and already lower: the Wegovy pill costs $149 to $299 a month by dose.
Is there a Wegovy shortage in 2026?
No. Semaglutide came off the FDA drug shortage list in February 2025, and Novo's 2026 report describes rising pill supply and launches in new countries rather than any shortage. Check with your pharmacy if a specific dose is hard to find locally.